Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 15.34
(4.85%)
CNY 15.34
(4.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 17.55 Million CNY | -33.94% |
| 2022 | 26.57 Million CNY | -75.38% |
| 2021 | 107.96 Million CNY | 357.87% |
| 2020 | 23.57 Million CNY | 175.96% |
| 2019 | -31.04 Million CNY | -63.31% |
| 2018 | -19 Million CNY | 30.22% |
| 2017 | -27.23 Million CNY | 50.95% |
| 2016 | -55.53 Million CNY | -6.07% |
| 2015 | -52.35 Million CNY | -109.96% |
| 2014 | -24.93 Million CNY | -7.31% |
| 2013 | -23.23 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.95 Million CNY | 92.5% |
| 2024 Q1 | -25.99 Million CNY | -200.83% |
| 2024 Q3 | 31.97 Million CNY | 1739.58% |
| 2023 Q4 | -8.64 Million CNY | -597.31% |
| 2023 Q3 | 1.73 Million CNY | -92.96% |
| 2023 FY | 17.55 Million CNY | -33.94% |
| 2023 Q1 | 2.34 Million CNY | 117.27% |
| 2023 Q2 | 24.69 Million CNY | 951.4% |
| 2022 Q2 | 37.84 Million CNY | 666.87% |
| 2022 Q1 | -6.67 Million CNY | -122.04% |
| 2022 FY | 26.57 Million CNY | -75.38% |
| 2022 Q4 | -13.59 Million CNY | -248.89% |
| 2022 Q3 | 9.13 Million CNY | -75.87% |
| 2021 Q2 | 21.91 Million CNY | 7.23% |
| 2021 Q4 | 30.29 Million CNY | -14.24% |
| 2021 Q1 | 20.43 Million CNY | 763960.97% |
| 2021 FY | 107.96 Million CNY | 357.87% |
| 2021 Q3 | 35.31 Million CNY | 61.16% |
| 2020 Q2 | 10.93 Million CNY | 421.85% |
| 2020 FY | 23.57 Million CNY | 175.96% |
| 2020 Q3 | 23.1 Million CNY | 111.3% |
| 2020 Q4 | 2674.95 CNY | -99.99% |
| 2020 Q1 | 2.09 Million CNY | 121.53% |
| 2019 Q1 | -15.89 Million CNY | 0.0% |
| 2019 FY | -31.04 Million CNY | -63.31% |
| 2019 Q4 | -9.73 Million CNY | 0.0% |
| 2018 Q1 | 423.1 Thousand CNY | -93.32% |
| 2018 Q2 | 423.1 Thousand CNY | 0.0% |
| 2018 FY | -19 Million CNY | 30.22% |
| 2017 Q4 | 6.33 Million CNY | 0.0% |
| 2017 FY | -27.23 Million CNY | 50.95% |
| 2017 Q1 | -5.99 Million CNY | 66.35% |
| 2017 Q3 | 6.33 Million CNY | 205.64% |
| 2017 Q2 | -5.99 Million CNY | 0.0% |
| 2016 Q1 | -9.93 Million CNY | 27.01% |
| 2016 Q4 | -17.82 Million CNY | 0.0% |
| 2016 FY | -55.53 Million CNY | -6.07% |
| 2016 Q3 | -17.82 Million CNY | -79.38% |
| 2016 Q2 | -9.93 Million CNY | 0.0% |
| 2015 Q3 | -13.61 Million CNY | -8.39% |
| 2015 Q2 | -12.56 Million CNY | 0.0% |
| 2015 Q1 | -12.56 Million CNY | 0.0% |
| 2015 FY | -52.35 Million CNY | -109.96% |
| 2015 Q4 | -13.61 Million CNY | 0.0% |
| 2014 FY | -24.93 Million CNY | -7.31% |
| 2013 FY | -23.23 Million CNY | 0.0% |